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Abstract Applications of tandem mass spectrometry (MS/
MS) techniques coupled with high-performance liquid chro-
matography(HPLC) inthe identificationanddeterminationof
phase I and phase II drug metabolites are reviewed with an
emphasis on recent papers published predominantly within
the last 6 years (2002–2007) reporting the employment of
atmospheric pressure ionization techniques as the most
promising approach for a sensitive detection, positive identi-
fication and quantitation of metabolites in complex biological
matrices. This review is devoted to in vitro and in vivo drug
biotransformation in humans and animals. The first step
preceding an HPLC-MS bioanalysis consists in the choice of
suitable sample preparation procedures (biomatrix sampling,
homogenization, internal standard addition, deproteination,
centrifugation, extraction). The subsequent step is the right
optimization of chromatographic conditions providing the
required separation selectivity, analysis time and also good
compatibility with the MS detection. This is usually not
accessible without the employment of the parent drug and
synthesizedorisolatedchemicalstandardsofexpectedphaseI
andsometimes alsophase IImetabolites.The incorporation of
additional detectors (photodiode-array UV, fluorescence,
polarimetric and others) between the HPLC and MS instru-
ments can result in valuable analytical information supple-
menting MS results. The relation among the structural
changes caused by metabolic reactions and corresponding
shifts in the retention behavior in reversed-phase systems is
discussed as supporting information for identification of the
metabolite. The first and basic step in the interpretation of
mass spectra is always the molecular weight (MW) determi-
nationbasedonthe presenceofprotonatedmolecules[M+H]
+
and sometimes adducts with ammonium or alkali-metal ions,
observed in the positive-ion full-scan mass spectra. The MW
determination can be confirmed by the [M-H]
- ion for
metabolites providing a signal in negative-ion mass spectra.
MS/MS is a worthy tool for further structural characteriza-
tion because of the occurrence of characteristic fragment
ions, either MS
n analysis for studying the fragmentation
patterns using trap-based analyzers or high mass accuracy
measurements for elemental composition determination
using time of flight based or Fourier transform mass
analyzers. The correlation between typical functional groups
found in phase I and phase II drug metabolites and
corresponding neutral losses is generalized and illustrated
for selected examples. The choice of a suitable ionization
technique and polarity mode in relation to the metabolite
structure is discussed as well.
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Introduction
Awide variety of manufactured and natural chemicals such as
drugs, industrial chemicals, pollutants, pesticides, pyrolytic
products from cooked food, secondary plant metabolites
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50005 Hradec Králové, Czech Republic(polyphenols, flavonoides, glycosides, terpenes, steroids,
alkaloids, antibiotics) and toxins from bacteria, molds,
plants and animals can influence the vital functions of an
organism and they represent serious risks for its homeostasis,
integrity and health. These categories of chemical compounds
are usually denoted as xenobiotics, foreign compounds or
exogenous compounds. The ability of the organism to cope
with exposure of xenobiotics is dependent on the existence of
various protective and defensive mechanisms leading to the
consecutive detoxication connected usually with an increase
of the hydrophilicity via metabolism and with the excretion of
modified xenobiotics from the organism.
This review is focused on the methodical approaches in
drug bioanalysis. Drugs are extensively employed xenobiotics
used for the prevention, diagnosis or therapy of various
diseases and pathological states. For the possibility to monitor
the movement of drugs in various body compartments, their
conversion in tissues and organs and their excretion from the
organism, suitable bioanalytical methods have to be developed
andvalidated.Thedevelopmentandvalidationofbioanalytical
methods involve sample preparation steps followed by the
separation of the drug and its metabolites from interfering
endogenous compounds and the detection of analytes by
various detection principles. Every experienced bioanalyst
should be familiar with the fate of the drug after its
administration into the body and the disposition of the
organism with thedrug molecule duringthemovement among
various body compartments. This information is very impor-
tant for the planning of required absorption–distribution–
metabolism–excretion (ADME) studies.
From thechemicalstructureandphysicochemicalproperties
of the drug, the bioanalyst should be able to forecast (1) the
probable behavior of the drug during its transfer through
various biological membranes and among various body
compartments and (2) the expected chemical structures of drug
metabolites formed during phase I and phase II biotransforma-
tion. This knowledge may help during the selection of suitable
sample preparation steps. In the subsequent instrumental
analysis, the selection of a suitable liquid-phase separation
technique and detection principle (photodiode-array, fluores-
cence, polarimetric, mass-spectrometric detection) should be
performed.
Pharmacological and xenobiochemical notes
The drug is administered in necessary doses usually repeat-
edly into the organism via parenteral (intravenous, intramus-
cular, subcutaneous, intraperitoneal), enteral (oral, sublingual,
rectal) orinhalationroutes[1, 2]. Transdermal administration,
when the drug is dosed on the skin together with an enhancer
of transdermal penetration, is sometimes also employed for
systemic drug delivery [3]. Further drug movement among
the individual compartments of the organism and its
interaction with the macromolecules (transporters, receptors,
enzymes, etc.) can be divided into four phases: absorption,
distribution, metabolism and excretion. Detailed information
about the fate of drugs in an organism is available in many
monographs [1, 2, 4, 5]. In this text only the basic facts
needed for the bioanalyst are discussed.
The absorption is the transfer of a drug from the site of
administration to the distribution compartment (bloodstream).
As the preparation of a sample from blood and its derivatives
(plasma, serum) is relatively simple, the identification and
determinationofthedruganditsmetabolitesinblood(plasma,
serum) is often employed in pharmacokinetic studies (includ-
ing bioequivalence studies). The actual concentration of the
drug (active metabolite) should range between subtherapeutic
and toxic concentrations. Therapeutic drug monitoring
employsbioanalyticalmethodsfortheindividualoptimization
of therapeutic dosing in patients with different ability to
absorb,metabolizeandexcretetheadministereddrug(patients
with intestinal, hepatic and/or renal malfunction). Bioequiva-
lence studies compare the pharmacokinetic parameters of two
drug forms (test vs. reference) administered sequentially to
volunteers and are also based on the instrumental determina-
tion of the drug or its active metabolite(s) [6, 7].
The drug distribution is the process by which the drug
leaves the bloodstream and enters the interstitium (extracel-
lular fluid) or the tissue cells, including target tissues for the
drug. The receptors located in target tissues interact with the
drug molecules and trigger the corresponding pharmacody-
namical (therapeutic) effect. If drug analysis in target tissue
is needed, the tissue sample has to be homogenized in a
suitable medium before further sample preparation steps.
The drug administered into the organism interacts not only
with above mentioned receptors but also with other macro-
molecules,suchasenzymesandnucleicacids.Duringthedrug
circulation in the organism, its chemical structure is usually
enzymatically modified [4, 5]. The sense of this drug
metabolism (biotransformation) consists in the increase of
drug hydrophilicity in order to facilitate its excretion from the
organism, predominantly via the uropoetic system and the
gastrointestinal tract. The modification of the chemical
structure of the parent drug is catalyzed by various drug-
metabolizing enzymes [8–11], which are localized prepon-
derantly in liver, but enzyme activities were also found in
lung, intestinum, kidney, brain and blood. When the drug is
administered orally, it may be absorbed from the gastrointes-
tinal tract by either passive diffusion or active transport via
carrier proteins. Being absorbed across the gastrointestinal
tract, the drug must traverse the portal system and undergoes
the so-called first-pass metabolism before entering the
systemic circulation [1, 4, 5]. Hence, the bioavailability of
drugs, which are rapidly metabolized by the liver or intestinal
enzymes, is relatively low, because the active drugs are
changed to more hydrophilic and usually inactive metabo-
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circulation and excreted via the uropoetic system; some of
them are transported from liver to bile and via the
gastrointestinal tract are excreted from the organism. The
enterohepatic recycling may prolong the pharmacological
effect of certain drugs and their metabolites [12]. Urine, bile,
intestinal content and feces contain large amounts of drug
metabolites. From the view of bioanalysts, these biomatrices
are most important sources of interesting chemical structures
formed during the drug biotransformation [13–17].
The reactions catalyzed by xenobiotic biotransforming
enzymes can be divided into two groups called phase I and
phase II reactions. Phase I reactions involve oxidation [8],
reduction [9–11], hydrolysis [18, 19] and some other less
frequent reactions, for example, chiral inversion [20, 21]. The
oxidation, reduction and hydrolysis reactions expose or
introduce a reactive functional group (–OH, –SH, –NH2, –
NH-, –COOH) in the molecule of parent drug. These phase I
metabolites, but also the parent drug possessing one or more
of the above mentioned functional groups, may significantly
increase their hydrophilicity during phase II biotransforma-
tion reactions by the conjugation of a xenobiotic molecule
(drug or its metabolites) with an eobiotic (endogenous)
molecule (glucuronic acid, amino acid, etc). Two of the
phase II reactions (acylation, methylation) cause increased
lipophilicity, but on the other hand the detoxication of an
irritant group in the molecule of the xenobiotic compound,
for example, 4-aminophenol → N-acetyl-4-aminophenol
(i.e., paracetamol), sulfane contained in flatus → dimethyl
sulfide. Most of these reactions (glucuronidation, sulfation,
conjugation with glutathione, GSH, amino acids) lead to a
large increase in xenobiotic hydrophilicity; hence, they
greatly promote the excretion of the drug from the body.
Sample preparation
A representative biomatrix sampling is the first important
step of an effective bioanalysis. The fluid samples (blood,
urine, bile) are mostly well accessible and treatable; the solid
samples (feces, tissues) have to be homogenized (Potter-
Elvehjem homogenizer or ultrasonic disintegrator) in a
suitable medium (for example, phosphate buffer). As early
as possible in the assay, a suitable amount of the chosen
internal standard should be added to account for losses and
errors introduced throughout the sample preparation process.
Analytes contained in the homogenized samples have to be
separatedfromendogenousmacromoleculesinthebiomatrix
and transferred into a solution containing the analytes
studied and only a minimized amount of endogenous
compounds. Many processes (filtration, centrifugation,
derivatization, solvent evaporation, solvent pH adjustment)
can be employed at this stage of bioanalysis in order to
increase the recovery of analytes during the final extraction.
The presence of any phase II metabolite in the biomatrix
can be preliminarily verified using xenobiochemical experi-
ments with β-glucuronidase and/or arylsulfatase [14, 17,
22–25]. These two enzymes are able to quite selectively
and quantitatively cleave the ether or ester bond between
glucuronicorsulfuricacidandthexenobioticpartofthephase
II drug metabolite under the back-formation of the phase I
drug metabolite. Comparative high-performance liquid chro-
matography (HPLC) analyses of the sample incubated
without an enzyme and the same sample after enzymatic
treatment using β-glucuronidase and/or arylsulfatase afford
qualitative and quantitative information about phase I and
phase II drug metabolites in the biological sample [14].
The derivatization is a chemical modification of the
analyte(s) in the sample leading to the stabilization of labile
molecule(s) before the instrumental analysis [26], to
increase the lipophilicity and extraction yield [27], to mask
functional group(s) causing separation problems during the
chromatography (e.g., esterification of carboxylic acids) or
to introduce a chromophore (fluorophore) into the molecule
of the analyte to improve spectrophotometric detection of a
weakly absorbing analyte (a detection-oriented derivatiza-
tion [28]). When HPLC–mass spectrometry (MS) analyses
are used, only the first three arguments for the derivatization
are plausible, but additionally the derivatization can lead to
the characteristic fragmentation applicable, for example, for
distinguishing positional isomers [29].
The extraction of the drug, its metabolites and the internal
standard is usually the final part of the sample preparation
process, enabling the preconcentration of analytes into a small
volume before the instrumental analysis. In the drug bioanal-
yses, the following types of extraction procedures are mostly
employed [30]: liquid–liquid extraction [31], solid-phase
extraction [32–34], solid-phase microextraction [35–37],
supercritical fluid extraction [38] and specific extraction using
molecularly imprinted polymers [39].
Bioanalysis based on HPLC-MS measurements combines
the separation efficiency of the chromatographic columns
with the detection power of MS. In general, MS is considered
to be one of the most universal tools for the identification and
determinationofxenobiotics.However,MSdetectionmustbe
preceded by separation techniques (e.g., HPLC, capillary
electrophoresis or gas chromatography after the derivation)
for the structural discrimination of positional isomers and
stereoisomers based on different retention times of positional
isomers [40] or stereoisomers [41], or additionally by
polarimetric or circular-dichroism detectors based on the
measurement of the changed direction of plane-polarized
light when passing through the individual concentration
zones of both enantiomers [41]. Figure 1 shows the
polarimetric detection (Fig. 1b) of two enantiomeric metab-
olites formed by the reduction of the keto group to a
secondary alcohol in comparison with UV detection
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should not be underestimated, because it can, in some cases,
differentiate the positional isomers, e.g., the position of O-
acetylation is identified on the basis of the UV spectra [17].
When metabolic products have a strong change in the
chromophoric system, UV spectra enable one to distinguish
different chromophoric groups of metabolites [40], e.g.,
dimeflurone has a carbonyl group in the conjugation with
three aromatic rings. When this carbonyl is reduced to
alcohol, the conjugation system and the corresponding UV
spectra are significantly changed (Fig. 2). The hyphenation
approach to the bioanalysis (the combination of HPLC with
photodiode-array UV, fluorescence, polarimetry, NMR and
MS as detection techniques) offers the most comprehensive
analytical information involving the chromatographic behav-
ior of individual analytes under study and the information
from individual detectors. These data are usually sufficient
for the identification of the chemical structures of unknown
metabolites and for their determination in the extract from
the biomatrix together with the parent compound.
High-performance liquid chromatography
The structural changes caused by metabolic reactions obvi-
ously have appropriate effects on the chromatographic
behavior of metabolites (Tables 1 and 2). In most cases, the
metabolic changes lead to an increased polarity of the
metabolites and therefore decreased retention in reversed-
phase (RP) HPLC systems in relation to the parent drug. The
polarity increase and simultaneous retention decrease effects
may be especially strong for phase II metabolites, for
example, sulfates, glucuronides and other polar conjugates
(Table 2). The separation of the parent drug and polar
metabolites in one chromatographic run usually requires the
use of gradient elution and often the addition of ionic
modifiers into the mobile phase to increase the retention of
polar conjugates [30]. Common HPLC methods for the
analysis of drugs and their metabolites without MS detection
frequently rely on the use of nonvolatile buffers and
additives, such as phosphate buffers and other inorganic
additives. These nonvolatile additives cannot be recommen-
Fig. 1 Chromatogram of reduced S- and R-enantiomeric metabolites
of flubendazole using a UV detection at 250 nm and b polarimetric
detection at 430 nm. (Adapted with permission from [41])
Fig. 2 Comparison of UV spectra of a the parent drug and related
metabolites with a keto group conjugated with three aromatic rings
and b metabolites with a keto group reduced to hydroxyl. (Adapted
with permission from [40])
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ination of the ion source and ion optics, and also strong
ion-suppression effects [42, 43]. The orthogonal geometry of
the ion source can somewhat reduce the contamination and
suppression effects [42], but anyway it is better to substitute
nonvolatile additives by more volatile analogs providing in
most cases comparable chromatographic performance. The
concentration of additives should be kept as low as possible,
maintaining the required retention selectivity as one aspect,
but avoiding the contamination and ion-suppression effects as
another point of view. Inorganic acids in the mobile phase
should be replaced by organic acids (formic or acetic acid)
with typical concentrations lower than 0.1% [44, 45], but
sometimes higher [46, 47]. For an alkaline environment,
ammonium hydroxide in a similar concentration range can be
used with HPLC columns with an extended stability at
alkaline pH [18, 48]. Typical volatile salts in HPLC-MS are
ammonium acetate or formate with a common concentration
range from 2 to 10 mmol/l [42, 49–52], rarely higher [30, 53].
Trifluoroacetic acid is a favorite ionic additive in bioassays
[54, 55], but it may cause serious ion-suppression effects in
HPLC-MS. If ion-pairing HPLC is needed for the successful
separation, then dialkylammonium or trialkylammonium
acetates or formates [42] are recommended for negatively
charged analytes and perfluorated carboxylic acids [43]f o r
positively charged analytes. For HPLC-MS analysis of chiral
drugs or metabolites formed with a new chiral center (e.g.,
keto reduction to alcohol [40, 56]), a chiral chromatographic
column should be used for proper analytical characterization
of metabolites [41, 57]. The typical column packings for
chiral separations of metabolites are α-acid glycoprotein
[58, 59], cellulose tris(3,5-dimethylphenylcarbamate) [41],
vancomycin [60], etc. Polarimetric detection is an obvious
detection choice for the chiral separation, because it can
distinguish enantiomers, unlike MS detection [61].
The current trend in pharmaceutical analysis is the reduction
of the analysis time and the increase in the sample throughput,
without sacrificing the separation selectivity. Various
approaches can be used to achieve these goals. The first
possibility is shortening the column length together with
reduction of the particle diameter. If the particle size is below
2 μm (sub-2-μm particles), then there is a substantial increase
of the column backpressure, which may be technically solved
by the development of instrumentation and columns surviving
such high pressures, so-called ultraperformance liquid chroma-
tography [49, 62–64]. Another important parameter is
temperature, because separation at increased temperature
reduces the analysis time and also decreases the column
backpressure owing to the decreased viscosity at higher
temperature [65]. In addition to C18 silica columns as the
gold standard in RP-HPLC, other packing materials may be
used as well, shorter alkyls C12 [54, 66]a n dC 8[ 67–69], a
medium-polarity nitrile column [70] for polar analytes or
longer alkyls such as C30 for hydrophobic drugs [34].
Hydrophilic interaction chromatography (HILIC) is based on
the hydrophilic interactions between ionic analytes and
zwitterionic groups covalently bonded to silica or polymer
beads, e.g., –CH2N
+ (CH3)2CH2CH2CH2SO3
-, which pro-
vides a separation mechanism orthogonal to that of RP-HPLC
[71]. The great potential of HILIC for polar phase II and also
phase I metabolites has been demonstrated in several papers
[55, 72, 73] and in many presentations at recent chromato-
graphic conferences. Ionic analytes often have little or no
r e t e n t i o ni nR P - H P L Ca n di o n i cmobile-phase additives are
troublesome because of MS coupling, so HILIC seems to be
the most promising direction for HPLC–tandem MS (MS/
MS) analysis of ionic metabolites. Another approach for ionic
metabolites is based on the combination of RP and weak
anion-exchange separation mechanisms applied in HPLC-MS/
MS [74]. An alternative approach to the architecture of
chromatographic columns packed with fine particles is the use
of monolithic columns [75]. Their high permeability allows
the use of higher flow rates and therefore shorter chromato-
graphic runs, as demonstrated for the separation of bupropion
metabolites in 23 s [75] at a flow rate of 2 ml/min, which may
require flow splitting in the HPLC-MS arrangement. In
general, the different types of column packing and column
type (particle vs. monoliths) offer different chromatographic
selectivity and therefore the fine-tuning of complex separa-
tions is feasible. The role of careful optimization of separation
conditions should not be overlooked even with MS/MS
detection, because some structural isomers cannot be distin-
guished by MS, e.g., positional isomers and enantiomers.
Another issue in biological analysis is the limited sample
amount, which directs attention to columns with reduced
inner diameter, such as microcolumns or capillary HPLC
columns [76, 77]. The most recent developments deal with
the use of separation on a chip, which may be easily
coupled with nanoelectrospray ionization [78] with ex-
tremely low sample and solvent consumption and enormous
sensitivity.
High-performance liquid chromatography–tandem mass
spectrometry
MS is considered the third most powerful spectral technique
in the structural elucidation of unknown organiccompounds,
but it has some distinct advantages over X-ray diffraction
and NMR spectroscopy in the field of bioanalytical assays.
MS can be easily coupled with both gas-phase and liquid-
phase separation techniques in the analysis of complex
biological samples, it has an extremely high sensitivity, low
sample consumption and required information may be
obtained relatively easily by a proper selection of ionization
technique and mass analyzer. For these reasons, HPLC-MS/
MS plays a prominent role in the analysis of biotransforma-
Anal Bioanal Chem (2008) 391:59–78 63Table 1 Effects of common phase I metabolic reactions on the mass-spectrometric behavior and retention in comparison with the parent drug
Nominal mass
shift (ΔDa)
Metabolic reaction (elemental
composition change)
Exact mass
shift (mDa)
Examples of relative
retention shift
a
References
– Azo reduction to amines
(R1N=N R 2 to R1NH2 +R 2NH2)
–– [145]
–14x
b Hydrolysis of esters to
carboxylic acid (-CxH2x)
–15.7x – [106]
–90 Reductive debenzylation (-C7H6) –47.0 0.74 [134][ 134]
–78 Reductive debromination (-Br+H) +89.5 – [113]
–74 Oxidative debenzylation (-C7H6+O) –52.0 – [180]
–68 Loss of CF3 (-CF3+H) +12.6 – [107]
–62 Oxidative debromination (-Br+OH) +84.4 0.39 [17][ 17]
–56 Debutylation (-C4H8) –62.6 – [107]
–45 Hydrolysis of nitrate to
alcohol (-NO2+H)
+14.9 – [113]
Reductive loss of nitro
group (-NO2+H)
+14.9 1.37 [46][ 46, 106]
–44 Decarboxylation (-CO2) +10.2 – [106]
–42 Depropylation (-C3H6) –47.0 0.73—isopropyl [131];
0.85, 1.09—propyl [24]
[24, 131]
–36 Loss of HCl (-HCl) +23.3 – [148]
–34 Reductive dechlorination (-Cl+H) +39.0 – [148]
–30 Nitro reduction to amine (-O2+H2) +25.8 0.75 [144][ 144]
–28 Deethylation (-C2H4) –31.3 0.87 [76][ 76]
–25 Reductive loss of nitrile
group (-CN+H)
+4.8 0.88 [45][ 45, 106]
–18 Alcohol dehydration (-H2O) +10.6 2.08
c [17][ 17]
Oxidative dechlorination (-Cl+OH) +33.9 0.73 [146][ 146]
Reductive defluorination (-F+H) +9.4 – [147]
–16 Desulfuration (-S+O) +22.8 0.54 [68][ 68]
Reduction of sulfoxide
to thioether (-O)
+5.1 – [113]
Reduction of hydroxylamine
to amine (-O)
+5.1 – [113]
–14 O-demethylation (-CH2) –15.7 0.88, 0.93 [19]; 0.56,
0.64 [40]; 0.59 [129];
0.87, 0.88, 0.90 [130]
[19, 25, 40, 46,
108, 129–131]
N-demethylation (-CH2) –15.7 0.82 [52]; 0.84 [135];
0.87 [51]; 0.88 [19];
0.90 [40]; 0.92 [133];
0.95 [130]; 0.99 [45]
[19, 40, 45,
47, 50–52, 130,
133, 135, 136]
S-demethylation (-CH2) –15.7 – [132]
–6 Aromatization of saturated
ring (-H6)
–47.0 – [152]
–2 Alcohol oxidation to
ketone/aldehyde (-H2)
–15.7 1.01 [83][ 83, 106]
Ring formation (-H2) –15.7 1.20 [112][ 112]
Oxidative defluorination (-F+OH) +4.3 – [77, 147]
–1 Oxidative deamination to
ketone/aldehyde (-NH3+O)
–31.6 – [142]
+1 Oxidative deamination
to alcohol (-NH+O)
–16.0 – [113]
Hydrolysis of amide
to carboxyl (-NH+O)
–16.0 – [143]
+2 Ketone/aldehyde reduction
to alcohol (+H2)
+15.7 0.72 [56]; 0.70 [40][ 33, 40, 56, 126]
Hydrogenation (+H2) +15.7 1.13 [124][ 17, 124]
Ring opening (+H2) +15.7 0.59 [149][ 47, 149–151]
64 Anal Bioanal Chem (2008) 391:59–78tion products [79]. HPLC-NMR coupling suffers from low
sensitivity, but if this obstacle can be overcome, then the
combination of HPLC-NMR and HPLC-MS/MS generates
superior data for full structure elucidation [80].
Ionization techniques
Owing to the large structural variety of all organic and
bioorganic molecules, there is not one universal ionization
Table 1 (continued)
Nominal mass
shift (ΔDa)
Metabolic reaction (elemental
composition change)
Exact mass
shift (mDa)
Examples of relative
retention shift
a
References
+14 Methyl/methylene oxidation
to aldehyde/ketone (+O-H2)
–20.7 0.92, 1.02 [102]; 1.05 [45][ 45, 102]
Alcohol oxidation to
carboxylic acid (+O-H2)
–20.7 – [106]
Hydroxylation and
cyclization (+O-H2)
–20.7 – [106]
+16 Hydroxylation (+O) –5.1 0.38 [51]; 0.40 [131]; 0.46
[137]; 0.46, 0.50, 0.62
[124]; 0.51, 0.73, 0.82,
0.89, 0.96 [76]; 0.56 [40];
0.58 [135]; 0.60, 0.62
[112]; 0.61 [45]; 0.69
[130]; 0.80 [52]; 0.82
[138]; 0.85 [102]
[23, 24, 40, 45,
47, 51, 52, 76,
83, 102, 108,
112, 124, 130,
131, 135–139]
Epoxidation (+O) –5.1 0.56 [124]; 0.72 [140];
0.89 [77]
[77, 124,
140, 141]
N-oxidation (+O) –5.1 0.93 [40]; 1.04 [45];
1.09 [76]
[40, 45, 51,
76, 131, 136]
S-oxidation of thioether
to sulfoxide or sulfoxide
to sulfone (+O)
–5.1 0.34 (S-SO) [141];
0.82 (S-SO) [138];
1.02 (SO-SO2)[ 143]
[138, 141, 143]
Aldehyde oxidation
to carboxyl (+O)
–5.1 – [126]
Oxidation and ring
formation (+O)
–5.1 0.46, 0.51 [137];
0.53, 0.64 [80]
[80, 137]
+18 Ring opening by water
addition (+H2O)
+10.6 1.10 [18][ 18, 19]
Hydrolysis of nitrile
to amide (+H2O)
+10.6 – [45]
+30 Methyl oxidation to carboxylic
acid (+O2-H2)
–25.8 0.24 [167]; 0.34 [40][ 40, 50, 167]
+32 Dihydroxylation (+O2) –10.2 0.49 [54]; 0.39 [124];
0.80, 0.81 [160]; 0.84
[83]; 0.63, 0.67, 0.71,
0.79, 0.94 [76]
[54, 76, 83,
124, 160]
S-oxidation of thioether
to sulfone (+O2)
–10.2 0.79 [138][ 138]
+34 Epoxidation and
hydration (+H2O2)
+5.5 0.39 [124]; 0.47 [140];
0.51, 0.68 [141]
[124, 140, 141]
+48 Trihydroxylation (+O3) –15.3 – [113]
S-oxidation of thiol
to sulfonic acid (+O3)
–15.3 – [113]
aThe parent drug has a relative retention shift (RRS) of 1.00.
bThe value of x corresponds to the length of the alkyl chain.
cRRS is related to another metabolite.
Anal Bioanal Chem (2008) 391:59–78 65Table 2 Effects of common phase II metabolic reactions on the mass-spectrometric behavior and retention in comparison with the parent drug
Nominal
mass shift
(ΔDa)
Conjugation reaction
(elemental composition
change)
Drug functional
group
Exact mass
shift (mDa)
Examples of relative
retention shift
a
References
+14 Methylation (+CH2)N H 2, OH, SH +15.7 – [114]
+28 Formyl conjugation (+CO) NH2,O H –5.1 1.59 [27][ 27]
+42 Acetyl conjugation (+C2H2O) NH2, NHNH2,
SO2NH2,O H
+10.6 1.24 [17],
1.11, 1.81 [27]
[17, 27]
+56 Propionyl conjugation (+C3H4O) NH2, OH +26.2 2.39, 3.17 [27][ 27]
+57 Glycine conjugation (+C2H3ON) COOH +21.5 0.70 [164][ 125, 164]
+70 Butyryl conjugation (+C4H6O) NH2, OH +41.9 6.50 [27][ 27]
+79 Phosphorylation (+PO3)O H –41.5 – [74]
+80 Sulfation (+SO3)N H 2,S O 2NH2,O H –43.2 0.41 [129]; 0.49 [135];
0.69, 0.92 [160]; 0.78 [83];
0.79 [51]; 0.81 [52];
1.13, 1.14 [154];
1.27, 1.37 [23]
[23, 25, 51, 52, 69, 74,
83, 93, 117, 129, 131,
134, 154, 158, 160]
+107 Taurine conjugation
(+C2H5O2NS)
COOH +4.1 – [125, 165]
+119 Cystein conjugation
(+C3H5O2NS)
Epoxide, halide +4.1 0.71 (-F+OH) [77][ 77, 117]
+129 Glutamine conjugation
(+C5H7O3N)
COOH +42.6 – [117]
+144 Carnitine conjugation
(+C7H14O2N)
COOH +102.5 – [181]
+160 Disulfation (+S2O6)N H 2,O H –86.4 – [120]
+161 N-Acetylcystein
conjugation (+C5H7O3NS)
Epoxide, halide +14.7 0.83 (-F+OH) [77][ 77, 117, 165, 182]
+162 Glucosylation (+C6H10O5) OH, COOH +52.8 0.55, 0.64 (cis),
0.79, 0.82, 0.90; (trans)
[158]; 0.67 [76]
[76, 117, 130,
154, 158]
+176 Hydroxyl O-glucuronidation
(+C6H8O6)
OH +32.1 0.41 [135]; 0.46 [53]; 0.63,
0.70 [157]; 0.65, 0.83 [55];
0.67, 0.82, 0.86 [154]; 0.74
[51]; 0.78 [52]; 0.78, 0.96
[23]; 0.99, 1.01 [158]
[17, 23, 25, 29, 30,
33, 46, 51–53, 55, 69,
74, 94, 120, 129, 135,
154, 156–159, 183]
Acyl O-glucuronidation
(+C6H8O6)
COOH +32.1 0.65 [44][ 25, 44, 85, 125,
182, 183]
N-glucuronidation (+C6H8O6)N H 2 +32.1 0.84 [160][ 33, 46, 130, 160, 183]
Quarternary N-glucuronidation
(+C6H8O6)
NR3 +32.1 0.31 [130]; 0.81 [53][ 33, 53, 130, 183]
S-glucuronidation (+C6H8O6) SH +32.1 – [183, 184]
C-glucuronidation (+C6H8O6) (CO)2CRH +32.1 – [153]
+220 Indirect carbamate
glucuronidation of
amines (+C7H8O8)
NH2+CO2 +21.9 1.09 [24][ 24, 50, 117]
+306-X Glutathione conjugation–
halide substitution
(-X+C10H16O6N3S)
Halide (X) +76.0 -X 0.72—fluoride [77][ 77]
+305 Glutathione conjugation
via epoxidation
(+C10H15O6N3S)
Aromatic +68.2 – [77, 101, 117, 123,
125–127, 161, 162]
+352 Diglucuronidation (+C12H16O12) OH, COOH,NH2 +64.2 – [154]
aThe parent drug has a RRS of 1.00.
66 Anal Bioanal Chem (2008) 391:59–78technique suitable for all drugs and their metabolites, but
several ionization techniques should be considered depend-
ing on the structure, compound polarity, molecular weight
(MW), etc. In HPLC-MS/MS coupling, three atmospheric
pressure ionization (API) techniques covers the whole
range of compound polarities and MWs—electrospray
ionization (ESI), atmospheric pressure chemical ionization
(APCI) and atmospheric pressure photoionization (APPI).
Moreover, the polarity mode can be chosen according to the
acidic, neutral or basic character of the analytes. In some
cases, the right choice of ionization technique and the
polarity mode is not so obvious; then measurements in all
available ionization modes should be the first step in the
optimization.
The softest ionization technique, ESI, is the method of
choice for polar to ionic compounds. This ionization
technique has promoted a great boom not only in proteomics
but also in drug metabolite identification, because it enables
the soft ionization of phase II metabolites, providing reliable
information on the MWs of these conjugates, unlike other
ionizationtechniques.For parentdrugandphase I metabolites
with a lower polarity, APCI and APPI may provide better
ionization efficiency and sensitivity [81, 82]. A better
tolerance to salts and matrix effects has been reported for
APCI [83] and APPI [84]i nc o m p a r i s o nw i t hE S I .A P P Ih a s
a similar application range as for APCI, but slightly extended
towards nonpolar compounds [85]. APPI is still a relatively
new and developing technique with a great potential in the
analysis of drug metabolites. The characteristic ions are the
same for all API techniques: the base peak of full-scan
positive-ion mass spectra is usually the [M+H]
+ ion often
accompanied by less abundant alkali-metal adducts [M+Na]
+
and [M+K]
+ [14], while the negative-ion mode typically
shows the peak of the deprotonated molecule [M-H]
- as the
base peak (most references in this review demonstrate such
behavior). APPI shows more frequently the formation of
radical molecular ions M
+.
, unlike other API techniques.
Depending on the mobile-phase composition, other adducts
m a yb eo b s e r v e da sw e l l ,f o re x a m p l e ,a m m o n i u ma c e t a t e
additive favors the formation of [M+NH4]
+ ions [14, 30].
Rarely, adducts with mobile-phase molecules are found, such
as [M+H+ acetonitrile]
+ or [M+H+ methanol]
+ [86, 87]. The
relative abundances of fragment ions in the full-scan spectra
are usually low to negligible, but there are known exceptions
with extensive fragmentation already in the full-scan spectra,
especially for APCI [88].
Matrix-assisted laser/desorption ionization (MALDI) is
the second most important ionization technique in proteo-
mics, but its role in drug metabolite identification is not as
high. The coupling with HPLC is usually performed in off-
line mode, because it offers some advantages over on-line
HPLC-MALDI-MS coupling. The effluent coming from the
HPLC column is deposited on the MALDI plate using an
xyz-positioning device deposited either as a continuous very
narrow trace or as distinct droplets in certain time intervals
[89]. The droplet deposition may affect the chromatograph-
ic resolution, so the continuous trace is preferred. The
deposition on the MALDI target with embedded matrix
allows one to decouple the chromatographic and mass-
spectrometric analyses. An important application of
MALDI is the imaging analysis of whole tissue, which is
useful for the characterization of distribution of metabolites
in individual organs [90, 91].
The discovery of desorption ESI (DESI) [92]s h o u l db e
mentioned among new developments in ionization tech-
niques with potential impact in drug metabolite identification
[93, 94]. The principle of DESI is based on the solvent
spraying through the stainless steel capillary with the applied
voltage, but the sample is not dissolved in the eluent but is
placed in front of the sprayed charged liquid, for example,
the slice of whole organ tissue or skin. This technique does
not require any sample preparation and may be used directly
for metabolite imaging of whole tissues or a living organism
to monitor where the metabolites are located [95]. Desorp-
tion interfaces are also available for other API techniques,
such as APCI [96], APPI [97] and the new ionization
technique of direct analysis in real time (DART) [98].
The whole review is devoted to the mass-spectrometric
analysis of ionized molecules, but in some cases also atomic
MS can provide useful information. The hyphenation of
HPLC with inductively coupled plasma MS can be used for
metabolite detection of drugs containing metals (e.g., Pt, Au
and Ru), halogens (I, Br and Cl) or sulfur [99, 100].
Mass analyzers
The function of a mass analyzer is the separation of ions
according to their different mass-to-charge (m/z) ratios. The
quality of mass separation is characterized by the degree to
which close m/z values can be separated in the mass
analyzer. The most practical definition of mass resolution
(R) is expressed as RFWHM = m/z /Δm/z, where m/z is mass-
to-charge value of the target peak and Δm/z is the full
width at half maximum of this peak. Mass analyzers are
classified into groups of low and high resolution. In
general, low-resolution mass analyzers (e.g., quadrupoles
and ion traps) have resolution in the low-thousands range,
while high-resolution analyzers should provide a minimum
resolution of 15,000 for time of flight (TOF) based
analyzers [42, 71, 101] or over 50,000 for Fourier transform
mass analyzers [102–104]. The advantage of ion traps (both
spherical and linear) is the possibility of MS
n scan, which is
useful for studying fragmentation paths [49, 105–108], as
illustrated for the example of the fragmentation pattern
determined on the basis of MS
n spectra (Fig. 3). The use of
high resolution is usually associated with another even
Anal Bioanal Chem (2008) 391:59–78 67more important parameter, mass accuracy, defined as
MA ¼ 106   m

zexp   m=ztheor
 
m=ztheor. High mass ac-
curacy measurements should routinely provide values
below 5 ppm with external calibration. Accurate masses
enable one to determine the right elemental formula among
different possibilities at a given nominal value or at least to
significantly reduce the number of possible formulas [42].
The determination of the most probable elemental formula
is performed in both MS and MS/MS modes, for molecular
adducts and fragment ions as well. The benefit of reliable
accurate mass measurements for the structural elucidation
of unknown metabolites is extremely high, especially in the
identification of unexpected or unusual metabolites.
An important issue in accurate mass measurements is the
right calibration of the mass scale and regular verification of
the precision of the measured masses within the calibrated
range [42, 102]. The best results should be obtained with
internal calibration, because the calibrant and the analyte
enter the mass analyzer at the same time, but on the other
hand suppression effects or mass interferences with the
calibrant masses may occur. To avoid interference with the
chromatographic separation, the calibrant can be introduced
after the column through a low-dead-volume T-piece or
even better using the second independent sprayer. Robust
instruments can provide comparable results even with
external calibration on the condition that the calibration is
performed as close as possible to the target analyte and no
drift of mass scale is apparent. The simplest technical
approach is the introduction of the calibrant in the void
volume of the chromatographic system and immediately
after the last chromatographic peak [109]. For longer runs,
additional calibrant can be injected using a six-port valve
and an infusion pump during the time when no compounds
are eluted. This approach is superior for accurate mass
measurements in the analysis of complex mixtures by
HPLC-MS, but the critical requirement is the stability and
robustness of the mass spectrometer. Other supporting
information for the right elemental composition determina-
tion is the comparison of the experimental isotopic
distribution with theoretically calculated patterns for all
elemental compositions considered, expressed as a σ value
[109, 110]. The use of an analog-to-digital converter is
essential for that purpose, because a time-to-digital con-
verter cannot provide such high precision of relative
abundances of individual isotopic peaks [111].
The most widespread tandem mass analyzer providing
high mass accuracy used in the metabolite identification is
the hybrid double-quadrupole TOF instrument [19, 64, 77,
101, 112]. Other analyzers based on Fourier transform
instruments exhibit even better mass accuracies, but at
significantly higher instrument costs, such as ion cyclotron
resonance (ICR) [104, 113] and Orbitrap as the newest
types of mass analyzer [102, 103]. The advantage of ICR is
significantly higher mass accuracy and resolution in
comparison with all available mass analyzers (better than
1 ppm with the external calibration, achievable sub-ppm
with the internal calibration), which often enables the
spectral analysis without HPLC separation. However, its
widespread is limited owing to high costs and also special
technical demands for the installation and operation. In the
past, double-focusing magnetic sector instruments had a
leading role in this area, but nowadays the abovementioned
mass analyzers offer clear advantages, such as more
favorable price, smaller size and easier operation.
When the benefits of individual types of tandem mass
analyzers for analysis of drug metabolites are compared,
trap-based analyzers are preferably used for studying the
fragmentation pathways, the triple-quadrupole analyzer is
the most suitable choice for quantitation, while TOF-based
analyzers or even better Fourier transform analyzers are
superior for elemental composition determination because
of high mass accuracy.
Metabolite structural changes compared
with HPLC-MS/MS behavior
The majority of HPLC-MS/MS applications in metabolite
identification are based on RP chromatographic systems. For
ionicandionizablecompounds,HILICseparationisbecoming
morepopularowingtotheselectivityorthogonaltothat of RP-
HPLC [71]. In the following discussion, we focus only on the
retention in RP-HPLC systems as the prevailing separation
mode for drug metabolites. In agreement with the definition
of metabolic processes of xenobiotics (see “Pharmacological
and xenobiochemical notes”), all metabolites should have a
higher polarity and lower retention in RP-HPLC in compar-
ison with the parent drug, with only a few exceptions, such as
acylation [27, 100], methylation [114] and some phase I
metabolic reactions (Tables 1 and 2). All other metabolites
Fig. 3 Radiochromatogram of monkey bile metabolites labeled with
14C. (Reprinted with permission from [24])
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shift (RRS), RRS ¼ tR; metabolite   tM
 
tR; parent drug   tM

,
should be in the interval (0, 1). It is not easy to provide a
generalization of RRSs in relation to individual metabolic
reactions, because various factors (e.g., mobile-phase com-
position, gradient steepness, column packing, positional
isomerism, drug structure) can significantly affect the RRS,
but regardless of these known limitations, Tables 1 and 2
show some distinct trends in the retention behavior of
metabolites.
In the drug metabolite identification, the structure of the
parent drug is always known; hence, the ionization and
fragmentation behavior can be studied first with the parent
drug and, if available, standards of phase I metabolites.
Then, this knowledge is applied by analogy for the
identification of unknown metabolites. Each metabolic
reaction leads to a characteristic change in the MWs of
the metabolites (Tables 1 and 2), which is the first indi-
cation for their identification. The mass shift is reflected
both for nominal masses in Daltons and for exact masses in
milliDaltons as well. Knowledge of the exact mass shift is
applicable for setting very narrow mass windows in
selected reaction monitoring (SRM) experiments, yielding
significantly increased selectivity of the determination
[113], or for the verification of proposed biotransformation
pathways [113]. It is worthwhile to apply the so-called
nitrogen rule which says that odd MW means an odd
number of nitrogen atoms, while even MW means either an
even number of nitrogen atoms or their absence. The
formation of nitrogen-containing metabolites (e.g., adducts
with amino acids, GSH) causes a characteristic change of
the odd/even character of MWs. For other basic interpre-
tation rules, reference to specialized literature for electron
ionization [115] and soft ionization techniques [88, 116,
117] is recommended. It should be kept in mind that MS is
mostly not applicable for distinguishing positional isomers
(except for isomers with functional groups on different
rings [29]), stereoisomers and enantiomers, so the support
of other separation and spectral techniques is essential
[117–119]. An established technique for in vivo metabolic
studies is labeling with radioactive isotopes, such as
14C
[24, 100, 120–122]o r
3H[ 24, 122, 123], where radio-
counting detection helps to positively identify metabolites
arising from the parent drug in complex biological
materials. Figure 4 shows a radiochromatogram of monkey
bile after treatment with a drug against anxiety disorder
labeled with
14C. Subsequently, drug metabolites detected
by radiocounting detection are identified using HPLC-MS/
MS and HPLC-NMR techniques [24].
Tables 1 and 2 were compiled on the basis of references
listed in this work and also our experiences and unpub-
lished works. The intention of these tables is to provide a
comprehensive list of common biotransformation reactions
occurring in humans and animals. Metabolic reactions can
occur multiple times or in combination with other reactions,
but these reactions are mostly not included here for better
clarity, with a few exceptions of important consecutive
reactions, such as double hydroxylation [76, 124], epoxi-
dation and GSH conjugation [101, 123, 125–127]. All
metabolites are sorted according to their nominal mass
shifts in comparison with the parent drug. Then the
metabolic reactions are described with their exact mass
shifts, RRSs and some selected references. The exact mass
shift is the deviation of the atomic masses from the nominal
values, for example, the exact mass of hydrogen is
1.007825, therefore the mass defect of hydrogen is
+0.007825 Da=+ 7.825 mDa (Table 3). If we consider that
current TOF-based mass analyzers can routinely measure
within an absolute mass error of ±1 mDa or mostly even
better, the relatively high differences in mass defects of
individual atoms (Table 3) and subsequently also metabo-
lites (Tables 1 and 2) can be applied in metabolite
identification. Another common tool in mass-spectrometric
studies of fragmentation pathways is the use of standards
labeled with stable isotopes [128]. In the case of biotrans-
formation studies, the combination of a nonlabeled and
labeled drug leads to twin peaks of metabolites with known
mass difference, which is helpful for studying the fragmen-
tation paths in tandem mass spectra [129].
Phase I metabolites
Concerning phase I metabolites, the only characteristic but
nonspecific neutral loss is usually the loss of water for all
metabolites containing hydroxyl functionality (typically for
aliphatic alcohols, less common for phenols) often observed
already in the full-scan mass spectra. Other less frequent
losses are CO2 (for all carboxylic acids formed either by
oxidation of alcohols and aldehydes or by the hydrolysis of
esters), H2S (for thiols formed by S-dealkylation), SO3 and
SO2 (for sulfonic acids formed by S-oxidation). Mostly,
phase I metabolites have lower retention in RP-HPLC except
for the following cases: denitration (RRS=1.37 [46]), ring
formation (RRS=1.20 [112]), hydrogenation (RRS=1.13
[124]) and hydration (RRS=1.10 [18]). Some metabolites
have retention very close to that of the parent drug, such as
methyl oxidation to aldehyde (RRS=0.92 and 1.02 [102],
RRS=1.05 [45]) and N-oxidation (RRS=0.93 [40], RRS=
1.04 [45]), RRS=1.09 [76] ) .I n t e r e s t i n g l y ,s o m em e t a b o l i t e s
show a very narrow retention window for different drugs,
positional isomers and chromatographic conditions, for
example, RRSs of eight N-demethylated metabolites are
within the range 0.82–0.99 (Table 1). On the other hand, the
most widespread phase I reaction, hydroxylation, yields
RRSs from 0.38 [51]t o0 . 9 6[ 76] for 20 different
metabolites, but most of them fit the region RRS=0.60–0.85.
Anal Bioanal Chem (2008) 391:59–78 69Fig. 4 Proposed metabolic pathways of AM-630 drug incubated with rat liver microsomes based on ion-trap MS
n spectra. (Reprinted with
permission from [150])
70 Anal Bioanal Chem (2008) 391:59–78One of the most common phase I biotransformation
reactionsisdemethylationoringeneraldealkylation(Table1).
Depending on the position of methyl/alkyl group, the
uncovered polar group can be amine (N-demethylation),
hydroxyl (O-demethylation) or thiol (S-demethylation). In
the case of nitrogen, there is often double alkyl substitution;
hence, two deakylations are necessary to uncover the amino
group. When the demethylation occurs, new hydroxyl [19,
25, 40, 46, 108, 129–131] or thiol [132] groups can undergo
fragmentation in MS/MS mode, yielding the typical neutral
losses of H2Oo rH 2S, respectively. In the case of the amino
group formed by N-demethylation [133], the neutral loss of
NH3 is not common. When the N,N-dimethyl group under-
goes the first demethylation, the characteristic neutral loss is
CH3NH2 (Δm/z 31) in comparison with CH3NHCH3
(Δm/z 45) for the parent drug, which can be used for
differentiation between competitive O-demethylation [27]. In
general, the dealkylation leads to the decrease of hydropho-
bicity and retention in RP-HPLC as well. The dealkylation
on the carbon atom is less common, except for losses of
bulky alkyls, such as tert-butyl [107]o rb e n z y l[ 134].
The oxidation is, in general, the introduction of an
oxygen atom by various reactions, such as hydroxylation
(one or multiple times) [23, 24, 40, 45, 47, 51, 52, 76, 83,
102, 108, 112, 124, 130, 131, 135–139] and aliphatic and
aromatic epoxidation [77, 124, 140, 141], which is often
followed by hydrolysis leading to dihydrodiol formation
[141]. Epoxides have the same elemental composition as
hydroxylated metabolites and similar retention behavior, so
their differentiation depends on the interpretation of their
mass spectra and UV spectra for aromatic epoxides. The
direct comparison of epoxide and hydroxylated metabolite
in the same position under identical chromatographic
conditions shows that the retention of epoxide is slightly
lower [124, 140]. Epoxides are normally unstable inter-
mediates, providing dihydrodiols by the subsequent hydra-
tion [141], but they may be detected for stabilized systems,
such as polyaromatic compounds [77, 124, 140]. A well-
known example of a stable epoxide is carbamazepine-
10,11-epoxide [124, 140]. The characteristic neutral losses
for dihydrodiols are two consecutive losses of water [141].
The oxidation of an already present functional group is
represented by the following examples: alcohol oxidation to
aldehyde/ketone [83, 106] and then to carboxylic acid
[126], amine to hydroxylamine and then to a nitro group
[107], oxidative deamination to aldehyde/ketone [142]o r
alcohol [113], thioether oxidation to sulfoxide [138, 141]
and then to sulfone [143]. Oxidation reactions lead to a
remarkable decrease of the relative retention in relation to
that of the parent drug, with one interesting exception of N-
oxide, where the retention is comparable [40] or even
slightly higher [45, 76]. Reduction reactions are less
frequent, but several biotransformation paths are known,
for example, nitro reduction to amine [144], the reduction
of azo bond functionality in organic dyes leading to two
aromatic amines [145] and ketone/aldehyde reduction to
secondary/primary alcohol [33, 40, 56, 126]. Positive-ion
MS/MS spectra of N-oxides can show unusual loss of an
OH
. radical (Δm/z 17), while negative-ion spectra tend to
show the formation [M+Cl]
- adducts unlike other metabo-
lites measured under the same experimental conditions
[40]. Hydrolysis reactions have been reported for esters
[106], nitrates [113], amides [143] and nitriles [45].
Organic halides can be degraded by oxidative (i.e.,
halogen is replaced by a hydroxyl group) [17, 77, 146, 147]
or reductive (i.e., halogen is replaced by hydrogen) [113,
147, 148] dehalogenation, where the former is more
frequent especially for biotransformation reactions or in
general any reaction under aerobic conditions. In addition
to these reactions, polyhalogenated xenobiotics (e.g.,
pesticides) can also provide stable metabolites formed by
the loss of HX, for example, the loss of HCl from the
banned pesticide DDT [148].
Metabolic reactions can also involve ring formation
[112] or ring opening [47, 149–151], often associated with
other oxidation and addition reactions. There are a wide
variety of other phase I reactions, which are relatively rare,
so only a few examples are listed in Table 1, such as
decarboxylation of carboxylic acid [106], reductive loss of
a nitrile group [45, 106], alcohol dehydration [17] and
aromatization of a saturated ring [152].
Figure 5 illustrates the benefit of isotopic labeling for
structural studies and fragmentation pattern recognition.
Figure 5a shows MS
2 and MS
3 spectra of the nonlabeled
drug 2-methylaminoethoxycarbonyl-4,4′-dimethoxy-5,6,5′,6′-
dimethylenedioxybiphenyl-2′-carboxylic acid (DDB-S),
while Fig. 5b shows the spectra for the d5-labeled drug.
When the labeled part of the molecule is retained during the
fragmentation, the fragment ion maintains the isotopic dif-
ference introduced by labeling. After the loss of the labeled
Table 3 Mass defects for common organic elements occurring in
biotransformation reactions
Element Nominal atomic
mass (Da)
Mass defect
(mDa)
H 1 +7.825
C1 2 0
N 14 +3.074
O1 6 –5.085
F1 9 –1.597
Si 28 –23.073
P3 1 –26.238
S3 2 –27.929
Cl 35 –31.147
Br 79 –81.662
I 127 –95.532
Anal Bioanal Chem (2008) 391:59–78 71moiety, the m/z values of both the labeled and the nonlabeled
fragments are identical.
Phase II metabolites
Glucuronidation is a major phase II metabolic pathway for
vertebrates (except for the cat family). The site of
glucuronidation (Fig. 6) is generally an electron-rich
nucleophilic heteroatom (O, N, S), in rare cases activated
carbon with suitable neighboring substitution, for example
1,3-dicarbonyl drugs sulfinpyrazone and phenylbutazone
[153]. The second most important biotransformation path is
the sulfate conjugation either with hydroxyl or amino
groups. These two reactions can occur multiple times
[154], if suitable functional groups are available in the
drug structure. If one drug gives both sulfate and
glucuronide conjugates, then glucuronide typically has a
slightly lower retention then the corresponding sulfate in
the same position [52]. Of course, this rule cannot be
generally applied for conjugates in different positions,
because the position of the conjugation has a comparable
or an even stronger effect on the retention. The formation of
polar phase II conjugates strongly affects the polarity,
chromatographic retention, ionization and fragmentation
behavior [117], because the most polar functional group in
the molecule usually induces the primary fragmentation
path. Phase II conjugates can be easily identified according
to the shifts of the nominal masses, exact masses and also
characteristic neutral losses (Table 2).
HPLC methods for the separation of glucuronides have
beenreviewedrecently[155]. Depending on the mobile-phase
composition, the adduct formation of [M+NH4]
+,[ M + N a ]
+
and [M+K]
+ can be observed in the positive-ion ESI mode in
addition to protonated molecules [M+H]
+, while the depro-
tonated molecule [M-H]
- prevails in the negative-ion ESI
mode [14, 94]. The most characteristic neutral loss for all
types of glucuronides is the loss of anhydroglucuronic acid
(Δm/z 176), which is observed in both polarity modes. The
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Fig. 5 MS
2 and MS
3 spectra measured with an ion-trap analyzer for a nonlabeled and b d5-labeled drug 2-methylaminoethoxycarbonyl-4,4′-
dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2′-carboxylic acid (DDB-S). (Reprinted with permission from [105])
72 Anal Bioanal Chem (2008) 391:59–78mass difference Δm/z 176 can be used in SRM for the
quantitation of glucuronides or for the sensitive detection of
glucuronides in complex biological mixtures using the neutral
loss scan. Hydroxyl O-glucuronide may also provide the
[M+H-193]
+ fragment ion in addition to the loss of Δm/z 176
[156]. If the drug has more potential sites for glucuronidation,
then more positional isomers [23, 55, 154, 157, 158]o r
multiple glucuronide conjugates [152] can be formed. The
identification of the conjugation site by MS is a difficult task
and the differentiation is mostly achieved only for conjuga-
tion sites on different aromatic rings. An interesting way for
differentiating between hydroxyl and acyl glucuronides has
been reported recently [25] based on the presence of the [M-
H-CO2]
- ion for hydroxyl glucuronides and the absence of
this ion for acyl glucuronides (Fig. 7). However, it is not clear
whether this case is specific or whether the rule can be
generally applied owing to the absence of other references.
Other attempts at the determination of the conjugation site are
based on the chemical derivatization with 2-chloro-1-methyl-
pyridinium iodide [29] or the formation of Co
2+ adducts with
the characteristic fragmentation [159]. In addition to the
abovementioned ions, repetitive losses of water up to four
molecules [14] can be observed in MS
n spectra of glucu-
ronides, but they do not have very high information content
for the structural elucidation. If the concentration of the
metabolite entering the mass spectrometer is too high, then
the dimeric ions [2M+Na]
+ and [2M+K]
+ or even trimeric
ions [3M+Na]
+ and [3M+K]
+ accompany common molecular
adducts [14]. In general, positive-ion ESI spectra provide
better results for the structural analysis of glucuronides,
because MS/MS spectra show diagnostic ions unlike the
negative-ion mode spectra, where the negative charge is
retained on the glucuronide moiety, so the negative-ion
spectra contain mainly deprotonated anhydroglucuronic acid
at m/z 175 and subsequent losses of CO2 and H2O( m/z 113)
and CO (m/z 85) [14, 117].
Typical neutral losses for sulfate conjugation are SO3
(Δm/z 80) and SO2 (Δm/z 64) [87, 154, 160], less
frequently H2SO4 (Δm/z 98). The presence of the ionic
sulfate group significantly induces the fragmentation
already in the full-scan spectra, which can lead to reduced
relative abundance of (de)protonated molecules. Some-
times, the radical ion [M-H-HSO3]
-. may occur [23].
Acetylation and other less common acyl conjugations with
formyl,propionylandbutyrylatthearomaticaminogrouplead
to increased hydrophobic character of metabolites and hence
significantly increased retention in RP-HPLC depending on
the length of acyl chain (Table 2). Characteristic neutral losses
for N-acylated metabolites are the following [27]: no neutral
loss for formyl, CH2CO for acetyl, CH3CHCO for propionyl
and CH3CH2CHCO for butyryl. O-acetylated metabolites
also provide neutral losses of CH3COOH (Δm/z 60) [17]o r
corresponding losses of other acyls.
Fig. 6 Different types of glucuronic acid conjugates: 1A hydroxy O-
glucuronide, 1B acyl O-glucuronide, 2A amino N-glucuronide, 2B amide
N-glucuronide, 2C sulfon amide N-glucuronide, 2D aliphatic quarternary
N-glucuronide, 2E aromatic quarternary N-glucuronide, 2F indirect
carbamoyl N-glucuronide, 3 thiol S-glucuronide, 4C -glucuronide
Fig. 7 Negative-ion electrospray ionization tandem mass spectrome-
try spectra of isomeric O-glucuronides: a hydroxy O-glucuronide, b
acyl O-glucuronide. (Adapted with permission from [25])
Anal Bioanal Chem (2008) 391:59–78 73Phase II metabolites formed by methylation do not have
any characteristic neutral loss, because the fragmentation of
methyl is apparent only in the case of the absence of any
other polar functional groups, for example, N-methylated
aniline provides the neutral loss of methyl radical [117].
GSH concentration in cells is up to 10 mM; therefore, GSH
conjugation is so frequent and important for biotransformation
reactions. There are two basic mechanisms of GSH conjuga-
tion [77, 117, 123, 125, 161, 162]. The first mechanism is the
substitution of aliphatic or aromatic halides by GSH. The
mass shift of this substitution of halides depends on the type
of halogen atom, generally expressed as -X+C10H16O6N3S.
The second mechanism is GSH conjugation via epoxide
formation, then the addition of GSH and the final dehydration
resulting in the mass shift +C10H16O5N3S[ 117, 125, 161,
162]. The isolation and detection of reactive GSH metabolites
is not a simple analytical task; therefore, an alternative
approach for studying reactive GSH metabolites was sug-
gested on the basis of on-line coupling of an electrochemical
cell and tandem mass-spectrometric characterization of the
products formed [163]. The mechanisms and fragmentation
paths for GSH conjugates are discussed elsewhere in more
detail [117]. The characteristic neutral loss is pyroglutamic
acid (Δm/z 129) [101, 161, 162], but other losses may occur
as well, such as glycine (Δm/z 75) [161, 162]a n d
characteristic cleavages known from peptide chemistry.
The conjugation of the carboxyl functional group via a
peptidic bond with amino acids is less common, but some
reports can be found for glycine [124, 164], glutamine [117]
and taurine [165]. Their identification is based on the
characteristic shifts of nominal and exact masses (Table 2)
and characteristic neutral losses in MS/MS spectra in a
similar manner as known from proteomics. The clear sign of
metabolites containing these amino acids is changed even/
odd characters of the MW in accordance with the nitrogen
rule. Characteristic neutral losses in the positive-ion ESI
mode are the losses of free acids, HCOOH (Δm/z 46) and
nonspecific loss of water (Δm/z 18), while in the negative-
ion ESI mode two characteristic ions are known, the neutral
loss of CO2 as for any carboxylic acid and the ion
corresponding to deprotonated amino acid, such as m/z 74
for the deprotonated glycine molecule [14].
Phosphorylation is a relatively rare biotransformation path
for xenobiotics [74]. The characteristic diagnostic ions for
multiple reaction monitoring transitions are [PO2]
- at m/z 63
and [PO3]
- at m/z 79. Glucosylation is the most important
reaction for plants and invertebrates, but its role in mammals
is rather limited [74, 158].
Quantitation
The established method for the HPLC quantitation of drugs
and their metabolites in biological samples is based on the use
of tandem mass-spectrometric detection and the right choice
ofinternalstandards[166]. Nowadays, single-stage MS is not
recommended for reliable bioanalytical quantitation, because
it suffers from insufficient selectivity in comparison with
MS/MS. Single-stage MS can only provide the selected ion
monitoring record at a certain m/z value, for example the m/z
value of [M+H]
+ or [M-H]
- ions, but the matrix or impurity
interferences may occur at the same m/z value; however, in
some specific cases of good chromatographic resolution and
the absence of matrix interferences, selected ion monitoring
may be considered as an alternative quantitative method.
Tandem mass-spectrometric analyzers have an additional
scan with utmost importance for the quantitative analysis in
complex matrices called selected reaction monitoring (SRM)
[54, 63, 68, 69, 75, 133, 157, 167]. The first mass analyzer
isolates the selected precursor ion (e.g., [M+H]
+ in positive-
ion mode or [M-H]
- in negative-ion mode) with a narrow
isolation width, then the second step is the fragmentation of
this ion by collision-induced dissociation in the second
analyzer (i.e., collision cell) and finally only one abundant
product ion with known m/z value is monitored by the third
analyzer. A typical example of a tandem mass analyzer used
for quantitation is a triple-quadrupole analyzer, where the
first quadrupole isolates the precursor ion, the second
quadrupole is used only for collision-induced dissociation
but not for mass analysis, and the third quadrupole detects
the product ions. Multiple reaction monitoring scan has the
same meaning as SRM but for more fragmentation reactions
in parallel [18, 58, 74, 83, 137, 138, 151, 168]. The typical
neutral transitions are related to the metabolite type, for
example, the neutral loss of SO3 (Δm/z 80) for sulfates, the
anhydroglucuronide unit for glucuronides (Δm/z 176) and
glucose for glucosides (Δm/z 162) [158].
Another important aspect is the appropriate choice of the
internal standard. The best approach is the use of isotopically
labeled analogs oftarget compounds (isotopomers).Ifsuchan
internal standard labeled with stable isotopes is added to the
biological sample before the sample preparation, the behavior
of labeled and that of nonlabeled compounds will be identical
inall commonanalyticalprocedures.Deuteratedanalogs have
no observable differences in their chromatographic retention
approximately up to six deuterium atoms [157], but a very
small retention shift can occur for higher deuterium numbers,
as illustrated for the example of d9–1-hydroxypyrene [168].
The only remarkable difference is found in their mass
spectra, because the m/z values are shifted by the
corresponding mass increment, which enables the parallel
peak area integration of nonlabeled target drug (or metabo-
lite) and labeled internal standard [74, 133, 167–169].
Another valuable application of deuterated analogs is the
verification of proposed fragmentation pathways [105].
The internal standard used for spectrophotometric
detection without MS should have a similar polarity,
74 Anal Bioanal Chem (2008) 391:59–78retention time sufficiently close to the compound(s)
determined and exhibit similar behavior during the sample
preparation procedures, e.g., comparable extraction recov-
eries. It is also desirable that the analytes and internal
standards should have the same or a similar chromophore
(fluorophore). From this point of view, the optimal internal
standards are structural homologs or analogs of the analyte(s)
under the study [28, 40, 41, 170].
In the development and validation of bioanalytical
methods, chemical standards of drug metabolites are needed.
These standards are sometimes accessible from commercial
sources, or they have to be isolated from a biomatrix [16],
biosynthesizedusing isolatedor/andimmobilized hepatocytes
[117, 171–173]o rs y n t h e s i z e d[ 27, 40, 56, 61, 170, 174–
176]. Many products of O-demethylation, N-demethylation,
N-oxidation, carbonyl reduction, etc. are simply accessible
by a modification of the parent drug structure [27, 40, 56,
170]. MS, NMR and HPLC purity control is required for
each of the newly synthesized standards. Syntheses of the
standards of phase II biotransformation products were also
described; some of these reactions are very simple (N-
acylation [27]), other reactions require an experienced
synthesist [61, 174–176].
Concluding remarks and future perspectives
This review is devoted to the HPLC-MS/MS characterization
of common phase I and phase II metabolites of xenobiotics.
Tables 1 and 2 provide the most comprehensive overview of
metabolic reactions occurring in human and animals reported
so far in relation to their HPLC-MS/MS behavior. However,
the list may not contain some rare metabolic reactions. The
interpretation of mass spectra was discussed and some general
conclusions were given for typical neutral losses associated
with individual phase I and phase II metabolic reactions. The
appropriate choices of ionization technique, polarity mode
and the type of mass analyzer were considered as well.
Concerning the future perspectives, some trends are
already notable at present. The available sample amount for
metabolite analysis is typically extremely low; therefore, the
use of nanotechnologies is desirable, e.g., capillary HPLC
columns or chip-based separations coupled with on-line
nanoelectrospray. Recently, several new ionization techniques
havebeenintroduced,suchasdesorptionAPI techniqueswith
potential in the spatial imaging of the distribution of
metabolites in individual organs and tissues, which can
provide better understanding of biotransformation processes.
Fast technical developments in mass-spectrometric instru-
mentation are resulting in better sensitivity, higher resolution,
better mass accuracy and also new types of mass analyzers
and ionization techniques. A side effect of this growth is the
extensive amount of analytical data, so manual interpretation
is becoming a speed bottleneck for high-throughput analysis;
therefore,sophisticatedsoftwarealgorithmsfortheprediction,
search and positive identification of both expected and new
metabolites are being developed and continuously improved
[107, 177–179] .H i g h - t h r o u g h p u ta n a l y s i si sb e c o m i n gm o r e
important, so the use of ultrafast separations combining
higher pressures, higher temperatures, faster flow rates,
shorter columns, etc. is being established in common
pharmaceutical analyses. Nowadays, the most powerful
combination of high-tech analytical instrumentation for the
structural elucidation of unknown metabolites is the coupling
of high-resolution/high mass accuracy HPLC-MS/MS,
HPLC-NMR and HPLC with radiocounting detection for
metabolites arising from the drug labeled with the radioactive
isotope, which can provide the maximum information
content, but the investment and operational costs of such
hypothetical ultrahyphenation are very high.
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